The relevant result to be available by the end of the year
The middle of the week came with good news from GlaxoSmithKline and Sanofi. The largest vaccine maker globally and the French drugmaker announced that their potential COVID-19 #vaccine would undergo human testing.
It all started in April when the two companies joined forces to develop a protein-based #COVID-19 vaccine, which so far showed promising results in clinical trials. According to them, the human clinical trial is designed to assess the vaccine's safety, tolerability, and immune response. If all goes well, the first results will be available by December. The clinical trial will occur at eleven sites across the US, and more than 400 people will take part.
Combined, GSK and Sanofi have the largest developing and manufacturing capability in the world, and their target is to produce 1 billion doses of vaccine in 2021.
To speed up the vaccine's development and to secure 100 million doses, the US government gave the companies $2.1 billion. Also, the UK is said to receive up to 60 million doses of vaccine if proven effective by undergoing trials.
The market reacted positively to the news, and GSK stock price gained more than 2%, while Sanofi added over 1%.
While you are here, don't forget to check-out our Corona Blend!
Sources: theguardian.com, finance.yahoo.com
Gli utenti / lettori non dovrebbero fare affidamento esclusivamente sulle informazioni qui presentate e dovrebbero fare le proprie ricerche / analisi anche leggendo la ricerca reale sottostante. Il contenuto è generico e non tiene conto di circostanze personali individuali, esperienza di investimento o situazione finanziaria attuale.
Pertanto, Key Way Investments Ltd non accetta alcuna responsabilità per eventuali perdite di trader a causa dell'uso e del contenuto delle informazioni presentate nel presente documento. Le performance passate non sono un indicatore affidabile dei risultati futuri.